FDA User Fees Should Be On Chopping Block – Legal Luminary Hutt
This article was originally published in The Gray Sheet
Executive Summary
FDA user fees are destructive to the agency's mission and should be discontinued, says Washington attorney and FDA expert Peter Barton Hutt
You may also be interested in...
FDA Scientific Capacity Inadequate; New Device Technology At Risk
CDRH is not equipped to understand the science behind many cutting-edge device technologies, says a Nov. 29 report from the Subcommittee on Science and Technology, an ad hoc panel of the FDA Science Board
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.